Skip navigation

BioWednesday London: Anti-infectives: From Science to IPO

18:00 - 21:00

QMB Innovation Centre, 5 Walden Street, London E1 2EF
01 March 2017
The field of anti-infectives has received a great deal of visibility over recent months, as strategies to combat the growing global challenge of anti-microbial resistance have emerged worldwide. Reinvigoration of the research base has been key to driving new thinking in this field, from diagnostics to therapeutics. 

The time is now for the great science to be translated into new technologies and products that enable better prevention, diagnosis and treatment of infectious diseases. A recurring challenge is how to create the value proposition, and hence investment case, to attract development funding from the private sector when the resultant products have uncertain markets. 

Setting the scene for a panel debate will be three exciting companies in the field along with an update from PharmaVentures on deal trends in the antimicrobial space and how investors are seeing returns.

18.00 - Registration and Networking

18.30 - Welcome from the Host and One Nucleus
Tony Jones, One Nucleus
Ramsay Richmond, Queen Mary BioEnterprises

18.35 - Introduction from PharmaVentures

18.40 - Case Study Presentations from Development Stage Companies

Case Studies:
Neem Biotech, Michael Graz
Auspherix, Neil Miller

19.05 - Panel Discussion - Is There a Market in the Antimicrobial Gap?

Summer Park, PharmaVentures

Michel de Baar
, MSD 
Chris Berry, PharmaVentures
Michael Graz, Neem Biotech 
Charles Hughes, Life Science Hub Wales 
Jo Pisani, PwC

19.55 - Closing Remarks

20.00 - Networking over Drinks and Canapés

21.00 - Close

Programme subject to change.


Members: free
Non-members: £50 (plus vat)
Academics: please contact

Title: BioWednesday London: Anti-infectives: From Science to IPO
Start: 2017-03-01 18:00:00Z
End: 2017-03-01 21:00:00Z